Case 1:20-cv-01644-RGA Document 1-44 Filed 12/03/20 Page 1 of 3 PageID #: 1259
`Case 1:20-cv-01644-RGA Document 1-44 Filed 12/03/20 Page 1 of 3 PageID #: 1259
`
`
`
`
`
`EXHIBIT 44
`
`
`
`
`
`EXHIBIT 44
`
`
`
`
`
`
`

`

`10/28/2020
`
`In-Lab Screening with NIPT | Turnkey sample-to-results in your lab
`Case 1:20-cv-01644-RGA Document 1-44 Filed 12/03/20 Page 2 of 3 PageID #: 1260
`
`23 CHROMOSOME PAIRS
`
`AND MORE
`
`Rethink prenatal screening.
`Think VeriSeq NIPT.
`
`View Video
`
` 
`
`Clinical / Reproductive and Genetic Health / Noninvasive Prenatal Testing (NIPT):
`
`NIPT has never performed better
`
`99.9%
`>
`
`26
`
`98.8%
`
`ACCURACY FOR T21, T18, T13
`
`HOURS
`
`FIRST PASS SUCCESS
`
`Superior performance. More confidence.
`
`It’s time to change the way you think about prenatal testing. The VeriSeq
`NIPT Solution v2 offers superior performance to any in vitro diagnostic
`(IVD) noninvasive prenatal testing (NIPT) solution available. With a
`sensitivity and specificity of >99.9% for trisomies 21, 18, and 13, a start-to-
`finish run time of just 26 hours, and a low sample failure rate, you can feel
`the confidence that comes with superior performance.
`
`Beyond performance, VeriSeq NIPT Solution v2 also offers coverage
`across the entire fetal genome, with the option to screen for aneuploidy for
`all chromosomes and partial duplications and deletions of 7 Mb or higher
`for all autosomes. Most NIPTs only give information on the status of
`common aneuploidies of chromosomes 21, 18, and 13. You may be missing
`something if you’re not looking genome-wide.
`
`Bring VeriSeq NIPT Solution into my Lab 
`
`Learn More about NIPT Sendout for Labs 
`
`1 T
`
`SOLUTION
`
`he PCR-free, automated and validated workflow is CE-
`marked and fully integrated from sample prep to NextSeq
`550Dx Sequencing System to assay software. With a
`comprehensive IVD solution, you have everything you need
`for NIPT using NGS. Watch how the VeriSeq NIPT Solution
`can take you from sample to results with an automated end-
`to-end workflow.
`
`View Video 
`
`https://www.illumina.com/clinical/reproductive-genetic-health/nipt/in-lab-screening.html
`
`1/2
`
`

`

`10/28/2020
`
`In-Lab Screening with NIPT | Turnkey sample-to-results in your lab
`Case 1:20-cv-01644-RGA Document 1-44 Filed 12/03/20 Page 3 of 3 PageID #: 1261
`
`Additional Resources
`
`The Clinical Value of NIPT
`
`NIPT Technology Guide
`
`Learn how noninvasive prenatal testing
`(NIPT) is making an impact around the
`world.
`
`Learn more about NIPT and key
`considerations when selecting a
`technology for screening with NIPT.
`
`Understanding the VeriSeq NIPT
`Solution Assay
`
`Dive into the VeriSeq NIPT assay and learn
`how it works.
`
`View Video
`
`Download Guide
`
`View Video
`
`Intended Use
`
`The VeriSeq NIPT Solution v2 is an in vitro diagnostic test intended for use as a screening test for the detection of genome-wide fetal genetic anomalies from maternal peripheral
`whole blood specimens in pregnant women of at least 10 weeks gestation. VeriSeq NIPT v2 uses whole-genome sequencing to detect partial duplications and deletions for all
`autosomes and aneuploidy status for all chromosomes. The test offers an option to request the reporting of sex chromosome aneuploidy (SCA). This product must not be used as the
`sole basis for diagnosis or other pregnancy management decisions.
`
`Limitations of the test
`
`Noninvasive prenatal testing (NIPT) based on cell-free DNA analysis from maternal blood is a screening test; it is not diagnostic. False positive and false negative results do occur.
`Test results must not be used as the sole basis for diagnosis. Further confirmatory testing is necessary prior to making any irreversible pregnancy decision. A negative result does not
`eliminate the possibility that the pregnancy has a chromosomal or sub chromosomal abnormality. This test does not screen for polyploidy (eg, triploidy), birth defects such as open
`neural tube defects, single gene disorders, or other conditions, such as autism. There is a small possibility that the test results might not reflect the chromosomal status of the fetus,
`but may instead reflect chromosomal changes in the placenta (confined placental mosaicism, CPM) or the mother that may or may not have clinical significance.
`
`Innovative technologies
`
`At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that
`were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet
`the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and
`providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling
`groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.
`For In Vitro Diagnostic Use. Not available in all countries and regions.
`
`Contact an Illumina representative for regional availability.
`
`© 2020 Illumina, Inc. All rights reserved.
`
`All trademarks are the property of Illumina, Inc. or their respective owners.
`For specific trademark information, see www.illumina.com/company/legal.html.
`
`Privacy Policy
`
`
`
`
`
`
`
`
`
`https://www.illumina.com/clinical/reproductive-genetic-health/nipt/in-lab-screening.html
`
`2/2
`
`